611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Mixing Marijuana With Opioids May Not Be Good for Mental HealthLarge Opioid Rx After Heart, Lung Surgery Often Leads to Misuse: StudyWhy Diet Sodas Aren't the Answer for Your Sugary Drink CravingsTB Cases Drop Among the Young, But Racial Disparities PersistCases of Lung Injury Tied to Vaping Keep RisingFish Oil Not a Magic Pill Against DiabetesFacing Up to a Lesser Known Form of Migraine PainDirty Air Is Deadly, Global Study ConfirmsSmoggy Air Might Contribute to Macular DegenerationMore Antibiotics, Higher Odds for Colon Cancer?The Merits of Physical TherapyVaping Constricts Blood Vessels, Raising Heart, Lung ConcernsWhen Does Heart Health Return to Normal After Quitting Smoking?New Antibiotic Approved for Community-Acquired Bacterial PneumoniaImplant Approved to Improve Symptoms in Advanced Heart Failure'No Quick Fix' for A-Fib, But Cardiologist Says You Can Help Prevent ItAHA News: Why Do Women Get Statins Less Frequently Than Men?'Dr. Google' Helps Some Patients Diagnose a Rare DiseaseHealth Tip: Recognizing a Staph InfectionIs Dairy Fat Different?CDC Recommends Catch-Up HPV Vaccination for Young AdultsHow to Relieve Dry, Irritated EyesPretomanid Approved for Treatment of Drug-Resistant TBAHA News: Tiring Easily May Warn of Future Heart TroubleAmerica's Obesity Epidemic May Mean Some Cancers Are Striking SoonerHeavy Smog as Bad as Pack-a-Day Smoking for LungsConcussed NFL Players Sidelined for Much Longer NowadaysHormone Therapy for Prostate Cancer Might Harm the Heart: StudyObesity and 'Spare Tire' Raise Hispanics' Odds for Early DeathAHA News: Protein Made During Long Workouts May Warn of Heart ProblemsHow to Help Your Heart Weather Extreme HeatHealth Threats Don't End for Some Sepsis SurvivorsHeat Waves Brought by Climate Change Could Prove Deadly for Kidney PatientsHealth Tip: Avoiding AnemiaAre You Still Putting Off Colon Cancer Screening?Tips for Preventing DiverticulitisFDA Reports More Seizures Among VapersKids Getting Too Many Opioids After TonsillectomyCan Major Surgeries Cause a Long-Term 'Brain Drain'?How Much Coffee Is Too Much for Migraine Sufferers?Steady Stream of Lesser Head Hits in Football Can Still Damage BrainDon't Sweat It: Hyperhydrosis Can Be TreatedFast-Food Joints on Your Way to Work? Your Waistline May WidenAdults Need Vaccines, TooHealth Tip: Managing Arthritis of the Hands'Selfies' Might Someday Track Your Blood PressureIn Heat Waves, Fans May Do More Harm Than GoodSmoking Creates Long-Lasting Risk for Clogged Leg ArteriesFootball Head Trauma Linked Again to Long-Term Brain DamageDrug Approved to Treat Tenosynovial Giant Cell Tumor
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Emgality Receives First FDA Approval for Treating Cluster Headache


HealthDay News
Updated: Jun 11th 2019

new article illustration

TUESDAY, June 4, 2019 (HealthDay News) -- The U.S. Food and Drug Administration granted Emgality (galcanezumab-gnlm) solution the first approval for treating episodic cluster headache, the agency announced yesterday.

Previously approved for preventive treatment of migraine in adults, Emgality is administered through patient self-injection. The recommended dosage of Emgality for treatment of episodic cluster headache is 300 mg administered as three 100-mg injections at the initial onset of cluster headaches and then monthly doses of 120 mg until the end of the cluster period.

The drug's approval for treatment of episodic cluster headache was based on a clinical trial of 106 patients. At three weeks, patients taking Emgality had 8.7 fewer weekly cluster headache attacks from baseline compared with 5.2 fewer attacks for patients who were taking placebo.

Injection site reactions were the most commonly reported side effect. Emgality puts patients at risk for hypersensitivity reactions and is contraindicated in patients with a serious hypersensitivity to galcanezumab-gnlm. The FDA states that patients should discontinue use if they experience such a reaction; hypersensitivity reactions could occur days after administration and could last for a prolonged period of time.

Approval was granted to Eli Lilly.

More Information